BiotechTube

LY3154207 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lewy Body Dementia

Conditions

Lewy Body Dementia

Trial Timeline

Nov 9, 2017 → Jul 10, 2020

NCT ID
NCT03305809

About LY3154207 + Placebo

LY3154207 + Placebo is a phase 2 stage product being developed by Eli Lilly for Lewy Body Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT03305809. Target conditions include Lewy Body Dementia.

What happened to similar drugs?

1 of 3 similar drugs in Lewy Body Dementia were approved

Approved (1) Terminated (0) Active (2)
✅E2020 + PlaceboEisaiApproved
🔄Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
🔄ACP-204Acadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04258826Phase 1Completed
NCT03305809Phase 2Completed
NCT02562768Phase 1Completed

Competing Products

13 competing products in Lewy Body Dementia

See all competitors
ProductCompanyStageHype Score
E2020 + PlaceboEisaiApproved
43
Donepezil HydrochlorideEisaiPre-clinical
26
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
40
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
35
E2027EisaiPhase 2
35
Irsenontrine + PlaceboEisaiPhase 2
35
E2020EisaiPhase 2
35
E2027EisaiPhase 1
29
HTL0018318 + PlaceboNxera PharmaPhase 2
27
ACP-204Acadia PharmaceuticalsPhase 3
44
ACP-204 + PlaceboAcadia PharmaceuticalsPhase 2
39
Neflamapimod + PlaceboCervoMedPhase 2
25
neflamapimodCervoMedPhase 2
29